Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) has received approval from the National Medical Products Administration (NMPA) to initiate a Phase I clinical study for its antibody drug conjugate (ADC) BL-M05D1, targeting locally advanced solid tumors.
BL-M05D1 utilizes the same “linker+toxin” platform as BL-B01D1, an EGFR/HER3-targeted ADC that was the focus of an USD 8.4 billion licensing agreement between Biokin and Bristol-Myers Squibb (BMS; NYSE: BMY), announced in December 2023. This strategic partnership underscores Biokin’s commitment to advancing innovative therapies in oncology.- Flcube.com
